Meeting
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
Authors
Tarek Mohamed Ahmed Abdel-Fatah
Nottingham Univ City Hosp NHS Trust, Nottingham, United Kingdom
Tarek Mohamed Ahmed Abdel-Fatah , Graham Ball , Daniel Yeo , Graham Hickman , Duncan Wheatley , Amandeep Singh Dhadda , Arlene Chan , Ian O. Ellis , Stephen Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 614)
DOI
10.1200/JCO.2023.41.16_suppl.614
Abstract #
614
Poster Bd #
444
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Expression relationships among EGFR family members and c-Met in esophagogastric adenocarcinoma.
First Author: Ellie Chan
Poster
2013 ASCO Annual Meeting
A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.
First Author: Takashi Ishikawa
Poster
2023 ASCO Annual Meeting
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.
First Author: Ryul Kim
Poster
2019 ASCO Annual Meeting
Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical changes which guides the optimal adjuvant therapy.
First Author: Tarek Mohamed Ahmed Abdel-Fatah